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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S227Conclusions: Our ﬁndings show that (a) Wnt/b-catenin signaling acts
anti-catabolic in human articular chondrocytes and especially inhibits
NF-kB-mediated catabolic events, whereas Wnt/b-catenin signaling in
mouse articular chondrocytes stimulates catabolic events, and that (b)
AnxA6 via stimulating NF-kB activity and inhibiting Wnt/b-catenin
signaling plays a major role in human cartilage degradation during OA
pathology. Our ﬁndings suggest that targeting AnxA6 function, espe-
cially its modulatory function of the NF-kB andWnt/b-catenin signaling
pathways may be a more effective way to control these signaling
pathways and their interactions during OA pathology than targeting
these individual pathways directly.
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CONTRAST-BASED MICRO-CT ANALYSIS OF MMP INHIBITOR
EFFICACY IN A RAT OSTEOARTHRITIS MODEL
T. Thote y, N.J. Willett y, M.A. Hart z, A.S. Lin y, S. Moran y, R.E.
Guldberg y, R.V. Kamath z. yGeorgia Inst. of Technology, Atlanta, GA,
USA; zAbbott Lab., Worcester, MA, USA
Purpose: Osteoarthritis (OA) is the most common degenerative joint
disease in humans and there are currently no clinically viable disease
modifying osteoarthritis drugs (DMOADs). Previous studies have tested
matrix metalloproteinase inhibitors (MMPis) in different animal models
and demonstrated efﬁcacy. In these studies, histopathology analysis has
been used as the traditional method to evaluate efﬁcacy of MMPi's. This
technique is time consuming, 2D, requires large samples sizes and
semi–quantitative. Equilibrium Partitioning of an Ionic Contrast Agent
based micro-CT (EPIC-mCT) imaging can be used to nondestructively
quantify changes in articular cartilage but has not previously been
applied to evaluate the efﬁcacy of DMOADs. Objective: Evaluate the
efﬁcacy of a broad spectrum MMPi (ABT-518 from Abbott Laboratories,
Abbott Park, IL) in the rat medial meniscal tear (MMT) model using
EPIC-mCT based quantitative parameters. Hypothesis: EPIC-mCT
provides a sensitive method to detect therapeutic effects of MMP
inhibition in a rat OA model.
Methods: Animal model: Weight matched male Lewis rats (275-300g)
were separated in three groups: Sham surgery, MMT +MMPi (30 mg/kg
orally twice a day for 21 days) and MMT+ vehicle (n¼14-15). All
surgeries were performed at Abbott Laboratories and approved by the
IACUC. m-CT Imaging: Joints were dissected and scanned following
equilibration in Hexabrix contrast agent. Images were evaluated for 3
volumes of interest (VOIs): (1) Only osteophytes (2) Medial 1/3 region of
medial tibial plateau cartilage (3) Only focal cartilage lesions (defect >
50% of cartilage thickness) on the medial plateau. Statistics: Data are
shown as means  SEM and analyzed via t-test or one-way ANOVA
(GraphPad Prism5 Software)
Results: Osteophyte: Representative coronal grayscale CT images show
the osteophytes in the vehicle MMT group compared to the MMPi
treated and sham group (Fig 1).
Figure 1. Delineation of osteophyte (OP) and representative images from experimental
groups.Quantitative EPIC-mCT showed signiﬁcantly higher total periph-
eral volume, mineralized peripheral volume, cartilaginous peripheral
volume and average 3D peripheral thickness in the vehicle MMT group
compared to MMPi treated group (Fig 2). No evidence of osteophytes
was observed in the sham animals. Cartilage: Representative imagesshow delineation of the medial 1/3 tibial plateau from the medial tibial
plateau and illustration of lesion vs. erosion sites (Fig 3 A, B). Cartilage
volume increased at 3 weeks in the vehicle MMT and MMPi treated
groups compared to the shams (Fig 3C). Lesion volumewas signiﬁcantly
lower in the MMPi group compared to the vehicle MMT group (Fig 3D).
The shams showed no lesions on the articular surface.
Figure 2. Quantiﬁcation of osteophyte parameters.Ă
Figure 3. Evaluation of medial 1/3 cartilage volume and lesion volume.ĂPower
analysis: A power analysis was performed to measure the minimum
number of samples required to detect differences in osteophyte
development between theMMPi treated and vehicle MMTgroups. Post-
hoc power analysis based on total peripheral volume indicated that
a minimum of 5 animals would be needed per group to detect
a signiﬁcant difference at a power > 0.8 and a ¼ .05.
Conclusions: In summary, 3D image analyses of retrieved joints indi-
cated that MMPi reduces focal lesion volume and osteophyte develop-
ment. Power analyses showed that the effects of the MMPi treatment
could be detected with as few as 5 samples per group when using EPIC-
mCT. This is the ﬁrst study to demonstrate the use of EPIC-mCTas a tool to
study efﬁcacy of potential DMOADs in rat MMT model of OA.
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BISPHOSPHONATE USE REDUCES PAIN AND RADIOLOGICAL
PROGRESSION IN PATIENTS WITH SYMPTOMATIC AND
RADIOGRAPHIC KNEE OSTEOARTHRITIS: DATA FROM THE
OSTEOARTHRITIS INITIATIVE
L.L. Laslett y, S.R. Kingsbury y, E.M. Hensor y, M.A. Bowes z, P.G.
Conaghan y. yUniv. of Leeds, Leeds, United Kingdom; z Imorphics Ltd,
Manchester, United Kingdom
Background: Bisphosphonate use has been studied in patients with OA,
with apparent mixed results. Effects on bone have generally been
positive: an observational study reported a 90% reduction in odds of
having a bone marrow lesion (BML) with the use of alendronate (OR
0.11, p0.05), whilst risedronate (50mg weekly) prevented an increase
in BML size over 24 months although this did not reach statistical
signiﬁcance. Risedronate (15 mg) reduced markers of cartilage
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toms or joint space narrowing over 2 years. Zoledronic acid reduced
knee pain and size of BML over 6 months. Overall, studies assessed
different medications, doses, endpoints and duration of observation;
the longest duration of observation in a clinical trial was 2 years.
Purpose: To investigate the effect of bisphosphonate use on symptoms
and structural progression of knee OA over four years of observation in
participants from the NIH Osteoarthritis Initiative
Methods: OAI participants with typical knee OA trial entry criteria (KL2/
3, minimum joint space width (mJSW) 2.5-5.0mm and pain 4 on
a numerical rating scale [NRS]) were classiﬁed as bisphosphonate users
(3 of the 5 years; n¼55) or non-users (no use in the preceding 5 years
or during follow-up; n¼268). Outcomes were pain (NRS, WOMAC),
WOMAC disability and stiffness, joint space narrowing (JSN), proportion
reporting radiological and radioclinical progression, and joint replace-
ment. Annual data over 4 years were analysed using linear mixed
modelling and generalised estimating equations, after adjustment for
age, BMI, and baseline pain where appropriate.
Results: Study patients were older women with knee OA, mean age
618.4 years (range 45-79), mean BMI 31.45.5 (range 18.8 - 48.7).
Bisphosphonate users were older, shorter, thinner, less physically active,
and more likely to be white than non-users. Bisphosphonate compli-
ance was 85% at year 1, reducing to 76% by year 4. Alendronate was the
most common bisphosphonate used (60-70%). NRS pain scores were
signiﬁcantly reduced among bisphosphonate users at years 2 and 3
(Year 3, -0.9 vs -2.2, p¼0.004), though not year 4, after adjustment for
baseline pain and analgesic use. Differences in WOMAC pain and
disability scores did not reach statistical signiﬁcance at any time point.
There was a trend to less JSN in bisphosphonate users over time (Year 4,
0.51mm vs 0.29mm; p¼0.06). Radiological progression (0.5 mm) was
reduced at year 3 (82% vs 11%, p¼0.041). Differences in rates of knee
replacement were not signiﬁcant.
Conclusions: We demonstrate reduction in pain intensity (NRS),
radiological progression and a trend to less JSN in bisphosphonate users
compared to non-users. Signiﬁcant reduction in NRS pain was observed
in the ﬁrst 3 years; diminution of effects by year 4 may reﬂect reduced
compliance, suggesting beneﬁcial effects may discontinue following
medication cessation. Differences in results obtained using NRS and
WOMAC may reﬂect different constructs measured by these tools. The
beneﬁcial trend on structural progression should be considered in
terms of the sample size.
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QUANTITATIVE 3D ANALYSIS OF CARTILAGE LESIONS AND
OSTEOPHYTES IN A RAT OA MODEL USING CONTRAST BASED
MICRO-CT IMAGING IN COMPARISON WITH HISTOPATHOLOGY
T. Thote y, N.J. Willett y, A.S. Lin y, S. Moran y, M.A. Hart z, R.V.
Kamath z, R.E. Guldberg y. yGeorgia Inst. of Technology, Atlanta, GA,
USA; zAbbott Lab., Worcester, MA, USA
Purpose: Development and characterization of small animal models
of osteoarthritis (OA) is an important for a better understanding of
OA pathogenesis and to evaluate disease modifying OA drugs
(DMOADs). A common surgical method of inducing OA involves
transecting the medial meniscus (MMT). The traditional method to
detect changes in articular cartilage is via histopathology which is
a time consuming and semi-quantitative process. Equilibrium Parti-
tioning of an Ionic Contrast Agent based micro-CT (EPIC-mCT) imaging
has recently been developed to characterize and quantify changes in
the articular cartilage. Objective: Quantify articular cartilage changes
as a function of time following MMT surgery and compare results
with independent histopathology data. Hypothesis: EPIC-mCT has the
sensitivity to detect and quantify articular cartilage damage and
osteophyte development
Methods: Animal model: Weight-matched male Lewis rats (275-300g)
underwent MMT on the right leg (n¼18) or sham surgery (n¼18) and
were sacriﬁced at 1, 2 and 3 weeks. m-CT Imaging: Joints were dissected
and scanned using a mCT 40 following equilibration in Hexabrix contrast
agent. Images were evaluated for 3 volumes of interest (VOIs): (1)
Medial 1/3 of medial tibial plateau (2) Only focal lesions on the medial
plateau (3) Only osteophytes (width > 200mm). Cartilage attenuation,
a quantitative metric inversely related to proteoglycan content was also
established. Focal defects were deﬁned as: erosions (defect < 50% of
thickness) or lesions (defect > 50% of thickness) (Fig 1) (All surgeries
were performed at Abbott Laboratories and approved by IACUC).Figure 1. Representative images of focal defects and osteophyte (OP) character-
ization.Histology: Histology was performed on the same samples after
decalciﬁcation, stained with Toluidine blue and scores were assigned by
a histopathologist. Statistics: Data are reported as mean  SEM and
analyzed with t-tests or one way ANOVA.
Results: Cartilage attenuation following MMT was signiﬁcantly
higher at week 2 and 3 compared to controls indicating lower
proteoglycan content (Fig 2). Similarly, histopathology scoring
showed a higher cartilage degradation score at week 2 and 3
compared to day 3 (Fig 2). Lesions were detected and quantiﬁed in
the MMT animals at week 2 and 3 with the maximum lesion volume
being observed in the MMT animals at week 3 (Fig 2). Areas of
erosion were evident one week post surgery; however lesions did not
begin to develop until week 2. There was a signiﬁcant increase in the
number and volume of lesions between weeks 2 and 3. Osteophyte:
Average peripheral thickness increased with time, consistent with 2D
histopathology data (Fig 3). Total peripheral volume, mineralized
peripheral volume and average 3D peripheral thickness were greater
for MMT animals compared to controls at weeks 2 and 3 (Fig 3).
Representative images show osteophytes both in histology and
micro-CT (Fig 3).
Figure 2. Comparision of histo-pathology data with CT data.Ă
Figure 3. Quantiﬁcation of osteophyte parameters.Ă
Conclusions: This study successfully demonstrates that progression of
joint degeneration can be detected by EPIC-mCT over the period of 3
weeks in the MMT model. Additionally, this is the ﬁrst instance of
quantiﬁcation of osteophyte development and mineralization in the
MMT model. Differences in osteophyte thickness and volume were
detected as early as 2 weeks via EPIC-mCT which could not be identiﬁed
via histology. At 3 weeks, EPIC-mCT data replicated 2D histopathology
data with the advantage of providing more detailed and quantitative
data while requiring fewer animals.
